Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05083182 · ClinicalTrials.gov registry record · Phase 3
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
A Phase 3 study of Arthritis, Juvenile, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT05083182: Active Phase 3 study of Arthritis, Juvenile, sponsored by Janssen Research & Development.
NCT05083182 is a Phase 3 study of Arthritis, Juvenile that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 50 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05083182, a Phase 3 study of Arthritis, Juvenile, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Primary Outcome
Steady-state trough serum concentration of ustekinumab at Week 28 by baseline age groups will be reported.
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Guselkumab
Study Locations (20)
Other
- STAT Research S A - Ciudad Autonoma Buenos Aires
- Hospital de Ninos de Cordoba - Córdoba
- Instituto Medico Platense - La Plata
- Instituto Caici - Rosario
- Centro Medico Privado de Reumatologia - San Miguel de Tucumán
- Aarhus Universitetshospital - Aarhus
- Odense Universitets Hospital - Odense
- CHU de Caen - Caen
- Hopital de Bicetre - Le Kremlin-Bicêtre
- Hopital Nord Marseille - Marseille
- CHU de Toulouse Hopital des Enfants - Toulouse
California
- Childrens Hospital Los Angeles - Los Angeles
- UCLA - Los Angeles
New York
- Northwell Health - New York
- Montefiore Medical Center - The Bronx
Massachusetts
- Harvard Medical School - Boston Children's Hospital - Boston
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Oregon
- Legacy Emanuel Medical Center - Portland
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-12-05 |
| Phase | Phase 3 |
What the registry record for NCT05083182 still lists
NCT05083182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Arthritis, Juvenile appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT05083182 names 20 study sites across 8 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05083182 about?
NCT05083182 is a clinical study titled "A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis". The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
What is the current status of trial NCT05083182?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-08-30. Estimated completion is 2026-12-05.
What conditions does trial NCT05083182 study?
This clinical trial studies the following conditions: Arthritis, Juvenile.
What interventions are being tested in trial NCT05083182?
The interventions under investigation include: Ustekinumab (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05083182?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05083182 being conducted?
This trial has 20 study locations across California, Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Juvenile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05083182's enrollment target sits among peer trials
50 1845th of 2000 higher than 141 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI